Synthesis of Rottlerone Analogues and Evaluation of Their α-Glucosidase and DPP-4 Dual Inhibitory and Glucose Consumption-Promoting Activity

Yinan Zhang 1, Haibo Wang 1, Yan Wu 1, Xue Zhao 1, Zhihong Yan 1, Robert H. Dodd 1,2, Peng Yu 1, Kui Lu 1,2,* and Hua Sun 1,2,*

1. Introduction

Diabetes mellitus is a multi-gene metabolic disease that is characterized by hyperglycemia that is caused by a relative (Type 2 Diabetes) or absolute (Type 1 Diabetes) insulin deficiency. The number of diabetes patients has been increasing rapidly in recent years due to changes in people’s living standards and dietary habits. The number of adult diabetes patients worldwide is about 463 million, and this number may reach 578 million by 2030, according to the statistical results of the International Diabetes Federation (IDF) in 2019 [1]. Diabetes is becoming one of the most widespread health burning problems in the elderly [2].

α-Glucosidase plays an important role in the physiological process of postprandial digestion and the absorption of carbohydrates in food in patients with Type 2 Diabetes, and it is the key enzyme involved in the hydrolysis of dietary carbohydrates [3]. α-Glucosidases specifically hydrolyze the α-1,4-glucopyranosidic bond to release glucose. Therefore, the inhibition of digestive α-glucosidase is one therapeutic approach to slowing down carbohydrate digestion and glucose absorption, thereby stabilizing blood glucose level and preventing hyperglycemia in diabetic patients. α-Glucosidase inhibitors have become a better choice in the case of Asian diabetic patients that are associated with high consumption of carbohydrates in their staple diet [4]. Dipeptidyl peptidase-4 (DPP-4) inhibitors enhance the plasma level of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinovertic polypeptide (GIP), which results in increased insulin
secretion and decreased glucagon secretion. It has been reported that the addition of a DPP-4 inhibitor to patients with type 2 diabetes that is inadequately controlled by an α-glucosidase inhibitor achieved better glycemic control without further increasing the risk of weight gain and hypoglycemia [5]. Thus, the development of dual inhibitors of α-glucosidase and DPP-4 may provide a novel approach to the discovery of new antidiabetic agents. To the best of our knowledge, such α-glucosidase and DPP-4 dual inhibitors have never been reported. It should be noted that the development of new α-glucosidase inhibitors has been largely neglected, since the introduction of acarbose, voglibose, and miglitol leave much room for the improvement of anti-diabetic therapies [3].

Desmethylnanthohumol (1, Figure 1), isolated from hops, has been found to display anticancer and antioxidant activity [6,7]. In a previous study, we found that desmethylnanthohumol inhibits α-glucosidase in vitro [8]. Furthermore, our recent investigations revealed that dehydrocyclodesmethylxanthohumol (2) and its dimer analogue rottlerone (3) [9] exhibited more potent α-glucosidase inhibitory activity than 1 (Figure 1). Therefore, we prepared a series of rottlerone derivatives 4a–4d and 5a–5d for the purpose of studying structure-activity relationships and improving the α-glucosidase inhibitory potencies of compounds 1–3. In addition, the synthesized compounds were also evaluated for DPP-4 inhibition with the goal of identifying potential dual-targeted anti-diabetic drugs.

Figure 1. Structures of 1–3 and rottlerone analogues.

2. Results

2.1. Synthesis and Characterization of Rottlerone Analogues

The synthesis of rottlerone analogues 4a–4d, 5a–5d, and 12–13 was accomplished, as shown in Scheme 1. The mono-MOM protected 2',4',6'-trihydroxyacetophenone (6) was synthesized from 2',4',6'-trihydroxyacetophenone according to a known procedure [10]. Compound 6 was converted to 7 by cyclization with 3-methyl-2-butenal, followed by removal of the MOM protection to provide 8. Conversion of the latter to dimer 9 was achieved by reaction with formaldehyde [11]. The rottlerone derivatives 4a–4h were then obtained by base-catalyzed aldol condensation of 9 with the corresponding substituted benzaldehydes. Deprotection of 4e–4h using 2M hydrochloric acid afforded 5a–5d. Finally, methylated rottlerone derivatives 12 and 13 were obtained by aldol condensation of compound 9 with benzaldehyde followed by O-methylation using CH$_2$N$_2$ in DCM.
**Scheme 1.** Synthesis of rottlerone derivatives. Reagents and conditions: (a) (1) MOMCl, DIPEA, DCM, r.t. 6 h, 82%. (2) 2 M HCl, MeOH, 30 °C, 3 h, 61%. (b) 3-methyl-2-butenal, pyridine, 120 °C, 75%. (c) 3 M HCl, MeOH, 30 °C, 6 h, 75%. (d) HCHO, DCM, reflux, 8 h, 71%. (e) R1CHO, 30% KOH, EtOH, 50 °C, 6 h, 56–88 %. (f) 2M HCl, MeOH, THF, 45 °C, 24 h, 70–81%. (g) CH₂N₂, DCM, r.t. 5 h, 30–44%.

2.2. Rottlerone Analogues Inhibited α-Glucosidase and DPP-4

The α-glucosidase and DPP-4 inhibitory activities of the synthesized compounds were evaluated. Acarbose and sitagliptin, clinically useful α-glucosidase and DPP-4 inhibitors, respectively, were chosen as the reference compounds for activity comparison. Dimer 9 was first evaluated and compared with the inhibitory activity of compound 2 and rottlerone (3), as shown in Table 1. Interestingly, replacement of the styrene moiety of rottlerone by a methyl group (9) led to a reduction in α-glucosidase inhibition. The variation of the electronic properties of para substituents on the phenyl group did not significantly alter the α-glucosidase inhibitory activity (4a and 4b vs. 3). However, the introduction of a hydroxy group at this para position (5a) resulted in a 10-fold improvement in activity. Furthermore,
the α-glucosidase inhibitory activities were found to be two-fold and four-fold higher than 5a in the case of the o,p-dihydroxyphenyl and o,m,p-trihydroxyphenyl derivatives 5b and 5d, respectively. The lower activity of the o,m-dihydroxy derivative 5c is perhaps due to the formation of an intramolecular hydrogen bond between the adjacent hydroxy groups. Notably, compound 5d also showed a modest DPP-4 inhibitory activity with an IC\textsubscript{50} = 26.19 µM. Altogether, these results revealed that free phenolic hydroxy groups are crucial for obtaining the desired activities.

Table 1. α-Glucosidase and DPP-4 inhibitory activities of rottlerone derivatives.

| Entry | α-Glucosidase (µM) \(\pm\) | DPP-4 |
|-------|------------------|-------|
| 1     | 22.42 ± 3.10     | >50   |
| 2     | 9.74 ± 0.73      | >50   |
| 3     | 5.91 ± 0.19      | >50   |
| 4a    | 6.41 ± 0.33      | >50   |
| 4b    | 8.71 ± 0.54      | >50   |
| 4c    | 1.84 ± 0.41      | 21.48 ± 0.09 |
| 4d    | 0.22 ± 0.07      | 23.59 ± 0.14 |
| 5a    | 0.51 ± 0.19      | >50   |
| 5b    | 0.24 ± 0.02      | >50   |
| 5c    | 1.07 ± 0.06      | >50   |
| 5d    | 0.12 ± 0.02      | 26.19 ± 0.22 |
| 9     | 7.11 ± 0.05      | >50   |
| 12    | 3.39 ± 0.13      | >50   |
| 13    | 0.37 ± 0.04      | >50   |
| Sitagliptin | -     | 0.08 ± 0.01 |
| Acarbose | 188.57 ± 5.52 | -     |

\(\text{a Results are the average of three independent experiments, each performed in duplicate.}\)

Compounds 4c and 4d, in which the phenyl ring is replaced by a furan or a thiophene ring, possessed three-fold and 26-fold higher α-glucosidase inhibitory activity than 3. Noteworthy, compound 3 demonstrated some degree of DPP-4 inhibitory activity (Table 1). This suggests that the phenyl ring of the rottlerone analogues can be advantageously replaced by a heterocyclic ring and it opens the way to a wide variety of further possible structural modifications to improve activity.

The methylation of the phenol hydroxyls on the 2H-chromene nucleus was also found to have considerable influence on α-glucosidase inhibitory activity. In particular, the trimethylated derivative 13 demonstrated a 10-fold enhancement of this activity when compared to the demethylated analogue 12 and comparable activity to that of 4d and 5d. We hypothesize that the 7-methoxy group prevents the formation of an H-bond between the 7- and 7′-hydroxyls, resulting in a vastly different steric environment favorable to α-glucosidase inhibitory activity.

2.3. The Enzyme Kinetics of Compounds 4d and 5d

The most active α-glucosidase inhibitors of our series, 4d and 5d, were then used for kinetic analyses in order to shed light on their mechanism of action. The plots of the velocity versus enzyme concentrations in the presence of different concentrations of 4d and 5d gave a family of parallel straight lines (Figure 2a,b). Increasing the inhibitor concentrations did not affect the slopes of the lines, indicating that 4d and 5d are irreversible inhibitors. Moreover, the value of 1/V increased with increasing concentrations of 5d, but the intercept on the X-axis and Y-axis remained constant. This result indicates that compound 5d is a mixed competitive α-glucosidase inhibitor.
2.4. Glucose Consumption of Compounds

In order to further study the anti-diabetic activity of compounds 4d and 5d, their effects on cell-based glucose consumption were evaluated using metformin as a positive control. Compound 5d was observed to significantly promote glucose consumption at 0.2 and 0.04 μM, while compound 4d showed similar potency at 0.2 μM, as shown in Figure 3.

Figure 3. Compounds 4d and 5d promoted glucose consumption in HepG2 cells. The data are the average of three independent experiments, each performed in duplicated. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. control.
3. Materials and Methods

3.1. Chemistry

All of the reagents and solvents were commercially available and used without further purification. The $^1$H NMR and $^{13}$C NMR spectra were recorded on a Bruker AM-400 NMR spectrometer (Billerica, Middlesex, MA, USA) in CDCl$_3$ or d$_6$-DMSO (dimethyl sulfoxide). Mass spectra were obtained on a Q-TOF mass spectrometer (Agilent, Santa Clara, CA, USA) and high resolution mass spectra were obtained on a hybrid IT-TOF mass spectrometer (Shimadzu LCMS-IT-TOF, Kyoto, Japan). Compound purity was determined by UV absorbance at 254 nm during tandem liquid chromatography/mass spectrometry (Agilent, Santa Clara, CA, USA). All of the final products had a purity of $\geq$95%, as determined using this method.

3.1.1. 1-(2,6-Dihydroxy-4-(methoxymethoxy)phenyl)ethan-1-one (6)

1-(2,4,6-Trihydroxyphenyl)ethan-1-one (1.68 g, 10 mmol) in dry CH$_2$Cl$_2$ (100 mL) were added N,N-diethylpropan-2-amine (3.93 g, 25 mmol) and chloro(methoxy)methane (1.77 g, 22 mmol) at 0 $^\circ$C. The reaction mixture was warmed to room temperature and then stirred for 6 h. The reaction was quenched with NH$_4$Cl (aq) and extracted with CH$_2$Cl$_2$ (500 mL) three times. The combined organic layers were washed with brine, dried over Na$_2$SO$_4$, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica (petroleum ether/ethyl acetate 20:1) to afford 1-(2-hydroxy-4,6-bis(methoxymethoxy)phenyl)ethan-1-one (2.1 g, 82%) as a colorless oil. 1-(2-hydroxy-4,6-bis(methoxymethoxy)phenyl)ethan-1-one (1.28 g, 5 mmol) in MeOH (50 mL) was added 2 N HCl (5 mL) at 0 $^\circ$C. After addition, the reaction mixture was warmed to 40 $^\circ$C and then stirred for 3 h. The reaction was quenched with NaHCO$_3$ (aq) and extracted with EtOAc (100 mL) three times. The combined organic layers were washed with brine, dried over Na$_2$SO$_4$, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica (petroleum ether/ethyl acetate 10:1) to afford a compound 6 (0.65 g, 61%) as a white solid. $^1$H NMR (400 MHz, d$_6$-DMSO) 12.26 (s, 2H), 6.02 (s, 2H), 5.17 (s, 2H), 3.36 (s, 3H), 2.58 (s, 3H). $^{13}$C NMR (100 MHz, d$_6$-DMSO) 203.8, 164.4, 163.6, 105.8, 95.1, 93.8, 56.3, 33.0.

3.1.2. 1-(7-Hydroxy-5-(methoxymethoxy)-2,2-dimethyl-2H-chromen-8-yl)ethan-1-one (7)

Compound 6 (2.12 g, 10.0 mmol) in dry pyridine (20 mL) was added 3-methyl-2-butenal (1.26 g, 15.0 mmol). The reaction was heated to 120 $^\circ$C for 16 h. The mixture was cooled and diluted with CH$_2$Cl$_2$ (20 mL). The mixture was poured into 5% HCl (aq, 20 mL). The organic phase was washed with NaHCO$_3$ (aq) (20 mL) and brine (3 x 20 mL). The organic phase was dried over Na$_2$SO$_4$ and then concentrated under reduced pressure. The crude product was purified by column chromatography on silica (petroleum ether/ethyl acetate 50:1) to afford a compound 7 (2.09 g, 75%) as a yellow oil. $^1$H NMR (400 MHz, d$_6$-DMSO) 13.64 (s, 1H), 6.58 (d, $J = 10.0$ Hz, 1H), 6.20 (s, 1H), 5.43 (d, $J = 10.0$ Hz, 1H), 5.20 (s, 2H), 3.47 (s, 3H), 2.67 (s, 3H), 1.50 (s, 3H). $^{13}$C NMR (100 MHz, d$_6$-DMSO) 202.4, 164.9, 157.4, 155.4, 123.8, 116.7, 105.5, 102.2, 93.2, 93.0, 77.0, 55.5, 32.2, 26.9.

3.1.3. 1-(5,7-Dihydroxy-2,2-dimethyl-2H-chromen-8-yl)ethan-1-one (8)

Compound 7 (2.12 g, 10.0 mmol) in dry pyridine (20 mL) was added 3-methyl-2-pentanone (1.26 g, 15.0 mmol) and then heated to 120 $^\circ$C for 16 h. The mixture was cooled and diluted with CH$_2$Cl$_2$ (20 mL). The mixture was poured into 5% HCl (aq, 20 mL). The organic phase was washed with NaHCO$_3$ (aq) (20 mL) and brine (3 x 20 mL). The organic phase was dried over Na$_2$SO$_4$ and then concentrated under reduced pressure. The crude product was purified by column chromatography on silica (petroleum ether/ethyl acetate 50:1) to afford a compound 7 (2.09 g, 75%) as a yellow oil. $^1$H NMR (400 MHz, d$_6$-DMSO) 13.64 (s, 1H), 6.58 (d, $J = 10.0$ Hz, 1H), 6.20 (s, 1H), 5.43 (d, $J = 10.0$ Hz, 1H), 5.20 (s, 2H), 3.47 (s, 3H), 2.67 (s, 3H), 1.50 (s, 3H). $^{13}$C NMR (100 MHz, d$_6$-DMSO) 202.4, 164.9, 157.4, 155.4, 123.8, 115.5, 105.5, 102.2, 93.9, 93.2, 77.0, 55.5, 32.2, 26.9.
3.1.4. 1,1’-(Methylenbis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (ethan-1-one) (9)

Compound 8 (1.0 mmol) in CH$_2$Cl$_2$ (10 mL) was added polyformaldehyde (0.5 mmol) and refluxed for 8 h. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica (petroleum ether/ethyl acetate 200:1) to afford a compound 9 (170 mg, 71%) as a yellow solid. $^1$H NMR (400 MHz, CDCl$_3$) 15.81 (s, 2H), 9.43 (s, 2H), 6.63 (d, $J = 10.0$ Hz, 2H), 5.43 (d, $J = 10.0$ Hz, 2H), 3.75 (s, 2H), 2.67 (s, 6H), 1.47 (s, 12H). $^{13}$C NMR (100 MHz, CDCl$_3$) 202.8, 160.2, 157.3, 154.9, 124.0, 116.0, 104.9, 104.0, 102.4, 77.1, 31.7, 26.9, 14.4. HRMS (ESI) $m/z$: calcd for C$_{27}$H$_{28}$O$_8$ [M + H]$^+$, 481.2656; found, 481.2604.

3.1.5. General Procedure for the Synthesis of Compounds 3 and 4a–4h

Compound 9 (0.5 mmol) in EtOH (3 mL) was added 30% KOH (aq, 1 mL) and substituted benzaldehyde (1.2 mmol) at 0 $^\circ$C. The reaction was heated to 50 $^\circ$C for 6 h. After cooling down to 0 $^\circ$C, 2N HCl was added to the reaction mixture until the pH = 5–6. The precipitate was filtered and then purified by column chromatography on silica to give compounds 3 and 4a–4d.

3.1.6. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-phenylprop-2-en-1-one) (3)

A red solid (0.266 g, yield 81%). $^1$H NMR (400 MHz, CDCl$_3$) 9.67 (s, 2H), 8.19 (d, $J = 15.6$ Hz, 2H), 7.83 (d, $J = 15.6$ Hz, 2H), 7.62–7.60 (m, 4H), 7.42–7.40 (m, 6H), 6.68 (d, $J = 12.0$ Hz, 2H), 5.47 (d, $J = 12.0$ Hz, 2H), 3.82 (s, 2H), 1.54 (s, 12H). $^{13}$C NMR (100 MHz, CDCl$_3$) 192.9, 162.8, 158.9, 155.4, 143.3, 135.5, 130.4, 129.0, 128.4, 126.8, 125.1, 117.3, 110.5, 103.8, 78.2, 28.0, 15.7.

3.1.7. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(4-methoxyphenyl)prop-2-en-1-one) (4a)

A red solid (0.270 g, yield 75%). $^1$H NMR (400 MHz, CDCl$_3$) 9.70 (s, 2H), 8.10 (d, $J = 15.6$ Hz, 2H), 7.83 (d, $J = 15.6$ Hz, 2H), 7.57 (d, $J = 8.8$ Hz, 4H), 6.95 (d, $J = 8.8$ Hz, 4H), 6.69 (d, $J = 9.6$ Hz, 2H), 5.48 (d, $J = 10.0$ Hz, 2H), 3.86 (s, 6H), 3.82 (s, 2H), 1.54 (s, 12H). $^{13}$C NMR (100 MHz, CDCl$_3$) 192.7, 162.9, 161.6, 158.7, 155.3, 143.4, 130.2, 128.3, 124.9, 124.4, 117.4, 114.5, 106.6, 105.3, 78.0, 55.4, 28.0, 15.8. HRMS (ESI) $m/z$: calcd for C$_{43}$H$_{40}$O$_{10}$ [M + H]$^+$, 717.3394; found, 717.3366.

3.1.8. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(4-fluoro phenyl)prop-2-en-1-one) (4b)

A red solid (0.270 g, yield 78%). $^1$H NMR (400 MHz, CDCl$_3$) 9.66 (s, 2H), 8.10 (d, $J = 15.6$ Hz, 2H), 7.79 (d, $J = 15.6$ Hz, 2H), 7.62–7.60 (m, 4H), 7.09–7.13 (d, 4H), 6.69 (d, $J = 9.6$ Hz, 2H), 5.48 (d, $J = 10.0$ Hz, 2H), 3.86 (s, 6H), 3.82 (s, 2H), 1.54 (s, 12H). $^{13}$C NMR (100 MHz, CDCl$_3$) 192.7, 162.8, 158.9, 155.4, 142.0, 131.8, 130.2, 128.3, 124.9, 124.4, 117.4, 114.5, 106.6, 105.3, 78.0, 55.4, 28.0, 15.7. HRMS (ESI) $m/z$: calcd for C$_{41}$H$_{34}$F$_2$O$_8$ [M + H]$^+$, 693.2394; found, 693.2301.

3.1.9. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(furan-3-yl)prop-2-en-1-one) (4c)

A white solid (0.253 g, yield 75%). $^1$H NMR (400 MHz, CDCl$_3$) 9.62 (s, 2H), 8.38 (d, $J = 15.6$ Hz, 2H), 7.69 (d, $J = 15.6$ Hz, 2H), 7.61 (d, $J = 15.2$ Hz, 2H), 7.47 (d, $J = 8.2$ Hz, 2H), 7.37 (t, $J = 7.6$ Hz, 2H), 7.25 (d, $J = 14.4$ Hz, 2H), 7.01 (s, 2H), 6.68 (d, $J = 7.2$ Hz, 2H), 5.51 (d, $J = 10.0$ Hz, 2H), 3.83 (s, 2H), 1.54 (s, 12H). $^{13}$C NMR (100 MHz, CDCl$_3$) 192.7, 162.8, 155.4, 155.4, 142.0, 131.8, 130.2, 130.1, 126.1, 125.1, 117.3, 116.3, 116.1, 106.5, 105.2, 103.8, 78.2, 28.0, 15.7. HRMS (ESI) $m/z$: calcd for C$_{41}$H$_{36}$O$_8$ [M + H]$^+$, 657.0782; found, 657.0760.
3.1.10. (2Z,2’Z)-1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(thiophen-3-yl)prop-2-en-1-one) (4d)

A red solid (0.271 g, yield 85%). 1H NMR (400 MHz, CDCl3) 9.68 (s, 2H), 8.02 (q, J = 18.0 Hz, 4H), 7.47–7.29 (m, 2H), 7.09 (d, J = 3.6 Hz, 2H), 6.67 (d, J = 9.6 Hz, 2H), 5.48 (d, J = 9.6 Hz, 2H), 3.81 (s, 2H), 1.56 (s, 12H). 13C NMR (100 MHz, CDCl3) 192.0, 162.9, 158.8, 155.3, 141.4, 136.0, 131.9, 128.6, 128.4, 125.9, 125.1, 117.1, 106.5, 105.1, 103.7, 78.2, 27.9, 15.7. HRMS (ESI) m/z: calcd for C37H32O8S2 [M + H]+, 669.3011; found, 669.3024.

3.1.11. (2Z,2’Z)-1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(4-(methoxymethoxy)phenyl)prop-2-en-1-one) (4e)

A red solid (0.343g, 88%). 1H NMR (400 MHz, CDCl3) 9.69 (s, 2H), 8.11 (d, J = 15.6 Hz, 2H), 7.82 (d, J = 15.6 Hz, 2H), 7.56 (d, J = 8.4 Hz, 4H), 7.08 (d, J = 8.8 Hz, 4H), 6.68 (d, J = 10.0 Hz, 2H), 5.48 (d, J = 10.0 Hz, 2H), 5.22 (s, 4H), 3.82 (s, 2H), 3.49 (s, 6H), 1.53 (s, 12H). 13C NMR (100 MHz, CDCl3) 192.7, 162.9, 159.1, 158.7, 155.3, 143.2, 130.1, 129.3, 125.0, 124.9, 117.4, 116.6, 106.6, 105.3, 103.8, 94.2, 78.1, 56.2, 28.0, 15.8.

3.1.12. (2Z,2’Z)-1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(2,4-bis(methoxymethoxy)phenyl)prop-2-en-1-one) (4f)

A red solid (0.250g, 56%). 1H NMR (400 MHz, CDCl3) 9.71 (s, 2H), 8.26 (d, J = 15.6 Hz, 4H), 8.09 (d, J = 16.0 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 2.4 Hz, 2H), 6.76 (dd, J = 8.8, 2.4 Hz), 6.68 (d, J = 10.0Hz, 2H), 5.47 (d, J = 10.0 Hz, 2H), 5.27 (s, 4H), 5.20 (s, 4H), 3.82 (s, 2H), 3.52 (s, 6H), 3.50 (s, 6H), 1.52 (s, 12H). 13C NMR (100 MHz, CDCl3) 192.9, 163.0, 160.5, 159.0, 158.6, 157.8, 155.3, 138.2, 128.4, 125.0, 124.7, 117.3, 117.4, 109.6, 106.9, 105.3, 103.7, 103.6, 94.8, 94.3, 78.0, 56.4, 56.3, 28.0, 15.8.

3.1.13. (2Z,2’Z)-1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(2,3-bis(methoxymethoxy)phenyl)prop-2-en-1-one) (4g)

A red solid (0.367g, 82%). 1H NMR (400 MHz, CDCl3) 9.70 (s, 2H), 8.30 (d, J = 15.6 Hz, 2H), 8.17 (d, J = 16.0 Hz, 2H), 7.34 (dd, J = 8.0, 1.2 Hz, 2H), 7.20 (dd, J = 8.0, 1.2 Hz, 2H), 7.09 (t, J = 8.0 Hz, 2H), 6.67 (d, J = 10.0 Hz, 2H), 5.48 (d, J = 10.0 Hz, 2H), 5.22 (s, 4H), 5.20 (s, 4H), 3.82 (s, 2H), 3.66 (s, 6H), 3.52 (s, 6H), 1.52 (s, 12H). 13C NMR (100 MHz, CDCl3) 192.9, 163.0, 158.8, 155.4, 150.5, 146.5, 138.4, 130.7, 127.7, 125.1, 124.6, 120.1, 118.2, 117.2, 106.6, 105.3, 103.8, 99.5, 95.2, 78.2, 58.0, 56.3, 28.0, 15.8.

3.1.14. (2Z,2’Z)-1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(2,3,4-tris(methoxymethoxy)phenyl)prop-2-en-1-one) (4h)

A red solid (0.397g, 76%). 1H NMR (400 MHz, CDCl3) 9.72 (s, 2H), 8.24 (d, J = 15.6 Hz, 2H), 8.13 (d, J = 15.6 Hz, 2H), 7.40 (d, J = 9.2 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 6.66 (d, J = 10.0 Hz, 2H), 5.47 (d, J = 10.0 Hz, 2H), 5.25 (s, 4H), 5.21 (s, 4H), 5.16 (s, 4H), 3.81 (s, 2H), 3.65 (s, 6H), 3.62 (s, 6H), 3.52 (s, 6H), 1.52 (s, 12H). 13C NMR (100 MHz, CDCl3) 192.7, 163.1, 158.7, 155.3, 153.2, 151.1, 139.7, 138.5, 125.9, 125.0, 124.6, 122.6, 117.3, 113.0, 110.6, 105.2, 103.7, 100.0, 98.8, 95.0, 78.1, 58.2, 57.4, 56.4, 28.0, 15.8.

3.1.15. General Procedure for the Synthesis of Compounds 5a–5d

Compounds 4e–4h (0.10 mmol) in MeOH (3 mL) and THF (3 mL) was added 2 N HCl (1 mL) at 0°C. After addition, the mixture was heated to 45°C for 24 h. The mixture was poured in cold NaHCO3 (aq, 10 mL) and then extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, and then concentrated under reduced pressure. The crude product was purified by column chromatography on silica (petroleum ether/ethyl acetate 4:1) to afford a compounds 5a–5d.

3.1.16. (2Z,2’Z)-1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(4-hydroxyphenyl)prop-2-en-1-one) (5a)

A red solid (55 mg, 81%). 1H NMR (400 MHz, d6-DMSO) 15.36 (s, 2H), 10.17 (s, 2H), 7.92 (d, J = 15.6 Hz, 2H), 7.72 (d, J = 15.6 Hz, 2H), 7.56 (d, J = 8.8 Hz, 4H), 6.87 (d,
J = 8.8 Hz, 4H), 6.63 (d, J = 10.0 Hz, 2H), 5.60 (d, J = 10.0 Hz, 2H), 3.78 (s, 2H), 1.50 (s, 12H).

\[13^C\] NMR (100 MHz, \(d_6\)-DMSO) 192.5, 163.6, 160.7, 154.5, 143.9, 130.9, 126.4, 125.7, 123.6, 117.2, 116.6, 107.3, 105.2, 103.0, 78.0, 27.9, 16.3. HRMS (ESI) m/z: calcd for C41H36O10 [M + H]^+, 689.2181; found, 689.2145.

3.1.17. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(2,4-dihydroxyphenyl)prop-2-en-l-one) (5b)

A red solid (50 mg, 70%). \(^1\)H NMR (400 MHz, \(d_6\)-DMSO) 16.20 (s, 2H), 10.41 (s, 2H), 10.06 (s, 2H), 8.16 (d, J = 15.6 Hz, 2H), 7.94 (d, J = 15.6 Hz, 2H), 7.36 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 10.0 Hz, 2H), 6.43 (d, J = 2.4 Hz, 2H), 6.34 (dd, J = 8.4, 2.0 Hz, 2H), 5.57 (d, J = 9.6 Hz, 2H), 3.75 (s, 2H), 1.49 (s, 12H). \[^{13}\]C NMR (100 MHz, \(d_6\)-DMSO) 192.8, 163.8, 162.0, 160.2, 154.7, 141.7, 132.52 125.7, 122.7, 117.2, 114.3, 108.7, 107.2, 105.1, 103.2, 103.1, 78.1, 27.7, 16.0. HRMS (ESI) m/z: calcd for C41H36O12 [M + H]^+ . 721.2279; found, 721.2280.

3.1.18. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(2,3-dihydroxyphenyl)prop-2-en-l-one) (5c)

A red solid (52 mg, 73%). \(^1\)H NMR (400 MHz, \(d_6\)-DMSO) 15.30 (s, 2H), 9.71 (s, 2H), 9.22 (s, 2H), 8.15 (d, J = 15.6 Hz, 2H), 7.99 (d, J = 15.6 Hz, 2H), 7.02 (d, J = 7.2 Hz, 2H), 6.86 (d, J = 7.6 Hz, 2H), 6.72 (t, J = 7.8 Hz, 2H), 6.61 (d, J = 10.0 Hz, 2H), 5.55 (d, J = 9.6 Hz, 2H), 3.76 (s, 2H), 1.48 (s, 12H). \[^{13}\]C NMR (100 MHz, \(d_6\)-DMSO) 193.0, 163.7, 154.6, 146.6, 146.3, 139.8, 126.5, 125.9, 122.7, 119.8, 119.4, 117.6, 117.2, 107.2, 105.3, 103.0, 79.6, 78.2, 27.8, 16.3. HRMS (ESI) m/z: calcd for C41H36O12 [M – H]--, 719.2134; found, 719.2112.

3.1.19. (2Z,2’Z)-1,1’-(Methylenebis(5,7-dihydroxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (3-(2,3,4-trihydroxyphenyl)prop-2-en-l-one) (5d)

A red solid (59 mg, 78%). \(^1\)H NMR (400 MHz, \(d_6\)-DMSO) δ 16.07 (s, 2H), 9.89 (s, 2H), 9.32 (s, 2H), 8.66 (s, 2H), 8.09 (d, J = 15.6 Hz, 2H), 7.98 (d, J = 15.6 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 10.0 Hz, 2H), 6.42 (d, J = 8.8 Hz, 2H), 5.56 (d, J = 10.0 Hz, 2H), 3.74 (s, 2H), 1.48 (s, 12H). \[^{13}\]C NMR (100 MHz, \(d_6\)-DMSO) δ 192.8, 163.7, 154.7, 149.9, 148.5, 133.5, 126.0, 122.7, 121.2, 117.1, 115.2, 108.5, 107.1, 105.2, 103.0, 79.6, 78.2, 27.7, 16.2. HRMS (ESI) m/z: calcd for C41H35O14 [M – H]^-, 751.2032; found, 751.2030.

3.1.20. General Procedure for the Synthesis of Compounds 10–11

A solution of KOH (20%aq, 20 mL) and ether (20 mL) was added methyl nitrosourea (1 g) at 0 °C and then stirred for 10 min. Compound 9 (1.0 mmol) in CHCl3 (10 mL) was dripped above ether solution at 0 °C. The reaction mixture was stirred for 6 h at r.t. The reaction was quenched with glacial acetic acid (0.1 mL) and then extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4, and then concentrated under reduced pressure. The crude product was purified by column chromatography on silica (petroleum ether/ethyl acetate 100:1 and 50:1) to afford compounds 10 and 11.

3.1.21. 1,1’-(Methylenebis(7-hydroxy-5-methoxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis (ethan-1-one) (10)

A yellow solid (0.150 g, yield 30%). \(^1\)H NMR (400 MHz, CDCl3) 13.79 (s, 2H), 6.46 (d, J = 10.0 Hz, 2H), 5.46 (d, J = 9.6 Hz, 2H), 3.87 (s, 2H), 3.64 (s, 6H), 2.67 (s, 6H), 1.48 (s, 12H). \[^{13}\]C NMR (100 MHz, CDCl3) 204.1, 163.7, 161.2, 155.0, 125.4, 117.7, 114.4, 108.0, 106.2, 65.8, 61.8, 33.5, 27.7, 15.2.

3.1.22. 1-(6-((8-Acetyl-5,7-dimethoxy-2,2-dimethyl-2H-chromen-6-yl)methyl)-7-hydroxy-5-methoxy-2,2-dimethyl-2H-chromen-8-yl)ethan-1-one (11)

A yellow solid (0.230 g, yield 44%). \(^1\)H NMR (400 MHz, CDCl3) 13.83 (s, 1H), 6.49 (d, J = 10.0 Hz, 1H), 6.44 (d, J = 10.0 Hz, 1H), 5.57-5.53 (d, J = 10.0 Hz, 1H), 5.47 (d, J = 10.0 Hz, 1H), 3.91 (s, 2H), 3.61 (s, 6H), 3.52 (s, 3H), 2.67 (d, J = 5.6 Hz, 3H), 2.50 (s, 3H), 1.48 (s, 6H), 1.40 (s, 6H). \[^{13}\]C NMR (100 MHz, CDCl3) 204.1, 201.9, 163.6, 161.1, 156.4, 156.3, 155.1, 149.1,
129.0, 125.5, 121.4, 120.6, 117.6, 117.1, 114.5, 111.2, 107.9, 106.3, 77.5, 76.4, 62.9, 62.1, 61.6, 33.5, 32.6, 27.6, 27.6, 17.6.

3.1.23. (2Z,2′Z)-1,1’-(Methylenebis(7-hydroxy-5-methoxy-2,2-dimethyl-2H-chromene-6,8-diyl))bis(3-phenylprop-2-en-1-one) (12)

Compound 10 (0.2 mmol) in EtOH (3 mL) was added 30% KOH (aq, 1 mL) and benzaldehyde (0.48 mmol). The reaction mixture was stirred at 50 °C for 6 h. After cooling down to 0 °C, 2 N HCl was added to the reaction mixture until the pH 5–6. The precipitate was filtered and dried to give compound 12 (104 mg, 88%) as a red solid.

1H NMR (400 MHz, CDCl₃) 13.95 (s, 2H), 8.07 (d, J = 15.6 Hz, 2H), 7.76 (d, J = 15.6 Hz, 2H), 7.62–7.57 (m, 4H), 7.46-7.34 (m, 6H), 6.48 (t, J = 11.4 Hz, 2H), 5.53-5.46 (m, 2H), 3.98 (s, 2H), 3.68 (s, 6H), 1.54 (s, 12H).

13C NMR (100 MHz, CDCl₃) 193.7, 164.3, 161.4, 154.4, 142.1, 135.6, 130.0, 128.9, 128.2, 127.9, 125.4, 117.8, 114.8, 108.5, 106.5, 61.9, 27.8, 17.0. HRMS (ESI) m/z: calcd for C₄₃H₄₀O₈ [M + H]^+, 685.3995; found, 685.3970.

3.1.24. (Z)-1-(6-((5,7-Dimethoxy-2,2-dimethyl-8-((Z)-3-phenylacryloyl)-2H-chromen-6-yl)methyl)-7-hydroxy-5-methoxy-2,2-dimethyl-2H-chromen-8-yl)-3-phenylprop-2-en-1-one (13)

Compound 11 (0.19 mmol) in EtOH (3 mL) was added 30% KOH (aq, 1 mL) and benzaldehyde (0.46 mmol). The reaction mixture was stirred at 50 °C for 6 h. After cooling down to 0 °C, 2 N HCl was added to the reaction mixture until the pH 5–6. The precipitate was filtered and dried to give compound 13 (117 mg, 87%) as a red solid.

1H NMR (400 MHz, CDCl₃) 14.00 (s, 1H), 8.07 (d, J = 15.6 Hz, 1H), 7.77 (d, J = 15.6 Hz, 1H), 7.60 (dd, J = 5.6, 1.8 Hz, 2H), 7.52 (dd, J = 6.6, 3.6 Hz, 2H), 7.44–7.39 (m, 4H), 7.39–7.32 (m, 5H), 7.03–6.97 (m, 1H), 6.55–6.50 (m, 1H), 6.49 (d, J = 9.8 Hz, 1H), 5.57-5.53 (m, 1H), 5.53–5.49 (m, 1H), 3.98 (s, 2H), 3.66 (s, 3H), 3.62 (s, 3H), 3.60 (s, 3H), 1.53 (s, 6H), 1.34 (s, 6H). 13C NMR (100 MHz, CDCl₃) 194.4, 193.7, 164.3, 161.3, 157.1, 156.5, 154.9, 149.8, 144.9, 142.2, 135.5, 134.9, 130.2, 130.1, 129.0, 128.9, 128.8, 128.4, 128.2, 127.7, 125.6, 120.4, 119.1, 117.8, 117.2, 115.0, 111.2, 108.5, 106.6, 77.5, 76.3, 62.6, 62.1, 61.7, 27.8, 27.6, 22.6, 17.8, 14.1. HRMS (ESI) m/z: calcd for C₄₄H₄₂O₈ [M + Na]^+, 733.2785; found, 733.2770.

3.2. α-Glucosidase Inhibition Assay

The commercially available α-glucosidase from baker’s yeast (Sigma, G5003) was selected as the target protein while using p-nitrophenyl-α-D-glucopyranoside (pNGP, Sigma, N1377) as the substrate. The compounds and acarbose were dissolved in DMSO. The enzyme and substrate were dissolved in potassium phosphate buffer (0.05 M, pH 6.8). The enzymatic reaction mixture that was composed of α-glucosidase (0.04 U, 20 µL), substrate (0.5 mM, 30 µL), test compounds (20 µL), and potassium phosphate buffer (130 µL) was incubated at 37 °C for 30 min. The enzymatic activity was detected by spectrophotometer at the wavelength of 405 nm. The results are the average of three independent experiments, each being performed in duplicate [8].

3.3. DPP-4 Inhibition Assay

The commercially available DPP-4 (PROSPEC, ENZ-375) was selected as the target protein using glycyl proline p-nitroaniline as the substrate. The compounds and sitagliptin were dissolved in DMSO. The enzyme and substrate were dissolved in Tris-HCl buffer (0.1 M, pH 8.0). The enzymatic reaction mixture that was composed of DPP-4 (0.01 U, 50 µL), substrate (2.2 mM, 50 µL), test compounds (10 µL), and Tris-HCl buffer (90 µL) was incubated at 37 °C for 30 min. The enzymatic activity was detected by spectrophotometer at the wavelength of 405 nm. The results are the average of three independent experiments, each being performed in duplicate [12].
3.4. Kinetics of Enzyme Inhibition

The kinetics of enzyme inhibition was performed with the same assays detailed above, in the presence of different concentrations of compounds 4d and 5d, substrate, and enzyme, respectively. The inhibitory kinetics of 4d and 5d on α-glucosidase was analyzed using the Lineweaver-Burk plot of the substrate concentration and velocity.

3.5. Glucose Consumption Assay

Briefly, the HepG2 cells were cultured in Dulbecco’s-modified Eagle’s medium (DMEM) containing 25 mmol/L D-glucose, 10% heat-inactivated fetal bovine serum (FBS), 10 U/mL penicillin, and 10 mg/mL streptomycin at 37 °C, 5% CO2 atmosphere. The culture solution was replaced every other day and then passaged once for 2–3 d. The cells were seeded into 96-well plate with twenty-four wells left as blanks. After reaching 70–80% confluence, the cells were washed with PBS twice and the medium was replaced by DMEM containing 25 mmol/L D-glucose to hunger for 24 h. The cells were washed with PBS twice and the medium was replaced by RPMI-1640 containing 11.1 mmol/L glucose that was supplemented with 0.2% bovine serum albumin (BSA). To the medium was then added 1 mmol/L metformin or purified product at different concentrations, and DMSO was used as the blank control. The glucose concentration in the medium determined a DMSO after 24 h treatment. Glucose consumption = glucose concentrations of blank wells − glucose concentrations of plated wells. The sulforhodamine B (SRB) assay was used to adjust the glucose consumption values. The SRB assay is based on the measurement of cellular protein content. After an incubation period, the cells were fixed with 10%, 4 °C trichloroacetic acid, stained for 1 h at 4 °C, and then washed with purified water. After drying, 60 µL SRB (3 mg/mL) was added into each well and then left at room temperature for 30 min. SRB was dissolved by 1% acetic acid before air drying. Bound SRB was solubilized with 150 µL Tris-base (10 mmol/L, pH 10.5) solution for OD determination at 546 nm while using a microplate reader [13].

4. Conclusions

A series of rottlerone analogues were synthesized and evaluated for their α-glucosidase and DPP-4 inhibitory activities. Compounds 4d and 5d were identified as new potent α-glucosidase inhibitors and moderate DPP-4 inhibitors. The kinetic analysis showed that compounds 4d and 5d are irreversible α-glucosidase inhibitors, and that 5d acts in a mixed competitive inhibitory mode. In addition, compounds 4d and 5d showed glucose consumption-promoting activity in HepG2 cells. Of these two compounds, the activity of 5d at 0.2 µM was comparable to that of metformin at a concentration of 1 mM. In view of these significant results, compound 5d, which combines both α-glucosidase and DPP-4 inhibitory activities, presents great potential as a lead compound for the development of a novel dual inhibitor treatment strategy for type 2 diabetes.

Author Contributions: Conceptualization, H.S. and K.L.; synthesis and characterization, Z.Y., H.W. and Y.W.; activity evaluation, X.Z. and Y.Z.; Writing—original draft preparation, Y.Z.; Writing—review and editing, H.S. and R.H.D. Funding acquisition, H.S., K.L. and P.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China (21502138) and the Natural Science Foundation of Tianjin (18JCYBJC94800).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: There are no data supporting.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: All samples are available from the authors.
References

1. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [CrossRef] [PubMed]

2. Longo, M.; Bellastella, G.; Maiorino, M.I.; Meier, J.J.; Esposito, K.; Giugliano, D. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Front. Endocrinol. 2019, 10, 45. [CrossRef] [PubMed]

3. Ghani, U. Re-exploring promising α-glucosidase inhibitors for potential development into oral anti-diabetic drugs: Finding needle in the haystack. Eur. J. Med. Chem. 2015, 103, 133–162. [CrossRef] [PubMed]

4. Hara, T.; Nakamura, J.; Koh, N.; Sakakibara, F.; Takeuchi, N.; Hotta, N. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996, 19, 642–647. [CrossRef] [PubMed]

5. Min, S.H.; Yoon, J.H.; Hahn, S.; Cho, Y.M. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis. J. Diabetes Investig. 2018, 9, 893–902. [CrossRef] [PubMed]

6. Delmulle, L.; Bellahcène, A.; Dhooge, W.; Comhaire, F.; Roelens, F.; Huvane, K.; Heyerick, A.; Castronovo, V.; De Keukeleire, D. Anti-proliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in human prostate cancer cell lines. Phytomedicine 2006, 13, 732–734. [CrossRef] [PubMed]

7. Vogel, S.; Ohmayer, S.; Brunner, G.; Heilmann, J. Natural and non-natural prenylated chalcones: Synthesis, cytotoxicity and anti-oxidative activity. Bioorg. Med. Chem. 2008, 16, 4286–4293. [CrossRef] [PubMed]

8. Sun, H.; Wang, D.; Song, X.; Zhang, Y.; Ding, W.; Peng, X.; Zhang, X.; Li, Y.; Ma, Y.; Wang, R.; et al. Natural Prenylchalconaringenins and Prenylnaringenins as Antidiabetic Agents: α-Glucosidase and α-Amylase Inhibition and in Vivo Antihyperglycemic and Antihyperlipidemic Effects. J. Agric. Food Chem. 2017, 65, 1574–1581. [CrossRef] [PubMed]

9. Jain, S.K.; Pathania, A.S.; Meena, S.; Sharma, R.; Sharma, A.; Singh, B.; Gupta, B.D.; Bhushan, S.; Bharate, S.B.; Vishwakarma, R.A. Semisynthesis of mallotus B from ror tierin: Evaluation of cytotoxicity and apoptosis-inducing activity. J. Nat. Prod. 2013, 76, 1724–1730. [CrossRef] [PubMed]

10. Teng, Y.; Li, X.; Yang, K.; Li, X.; Zhang, Z.; Wang, L.; Deng, Z.; Song, B.; Yan, Z.; Zhang, Y.; et al. Synthesis and antioxidant evaluation of desmethylxanthohumol and their dimers. Eur. J. Med. Chem. 2017, 125, 335–345. [CrossRef] [PubMed]

11. Akbaba, Y.H.T.; Gksu, S.; Ertan, A.; Menzek, A. Total Synthesis of the Biologically Active, Naturally Occurring 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(methoxymethyl)benzyl)benzene-1,2-diol and Regioselective O-Demethylation of Aryl Methyl Ethers. Helv. Chim. Acta 2010, 93, 1127–1135. [CrossRef]

12. Parmar, H.S.; Jain, P.; Chauhan, D.S.; Bhinchar, B.K.; Munjal, V.; Yussuf, M.; Choube, K.; Tiwari, A.; Chawla, V.; Manivannan, E.; et al. DPP-IV inhibitory potential of naringin: An in silico, in vitro and in vivo study. Diabetes Res. Clin. Pract. 2012, 97, 105–111. [CrossRef] [PubMed]

13. Sun, C.; Yan, Y.; Chen, Q.; Luo, F.; Zhu, X.; Li, X.; Chen, K. Purification of naringin and neohesperidin from Huyou (Citrus changshananensis) fruit and their effects on glucose consumption in human HepG2 cells. Food Chem. 2012, 135, 1471–1478.